AR113692A1 - Polipéptidos de fusión biespecíficos y sus métodos de uso - Google Patents

Polipéptidos de fusión biespecíficos y sus métodos de uso

Info

Publication number
AR113692A1
AR113692A1 ARP180103268A ARP180103268A AR113692A1 AR 113692 A1 AR113692 A1 AR 113692A1 AR P180103268 A ARP180103268 A AR P180103268A AR P180103268 A ARP180103268 A AR P180103268A AR 113692 A1 AR113692 A1 AR 113692A1
Authority
AR
Argentina
Prior art keywords
fusion polypeptides
use methods
specific fusion
methods
fusion proteins
Prior art date
Application number
ARP180103268A
Other languages
English (en)
Inventor
Godfrey Jonah Rainey
Michelle Turnham
Jonathan Seaman
Simon Dovedi
Michael Oberst
Scott Hammond
Ronald Herbst
Ryan Gilbreth
Yue Wang
John Mumm
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of AR113692A1 publication Critical patent/AR113692A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan proteínas de fusión biespecíficas y métodos de uso de las proteínas de fusión biespecíficas para tratar el cáncer.
ARP180103268A 2017-11-09 2018-11-09 Polipéptidos de fusión biespecíficos y sus métodos de uso AR113692A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762583723P 2017-11-09 2017-11-09

Publications (1)

Publication Number Publication Date
AR113692A1 true AR113692A1 (es) 2020-06-03

Family

ID=66438634

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103268A AR113692A1 (es) 2017-11-09 2018-11-09 Polipéptidos de fusión biespecíficos y sus métodos de uso

Country Status (13)

Country Link
US (1) US20190241659A1 (es)
EP (1) EP3706786A4 (es)
JP (1) JP2021502360A (es)
KR (1) KR20200079536A (es)
CN (1) CN111315405A (es)
AR (1) AR113692A1 (es)
AU (1) AU2018364562A1 (es)
BR (1) BR112020008978A2 (es)
CA (1) CA3081353A1 (es)
MX (1) MX2020004801A (es)
RU (1) RU2020118832A (es)
TW (1) TW201934583A (es)
WO (1) WO2019094574A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220267436A1 (en) * 2019-07-23 2022-08-25 Nanjing GenScript Biotech Co., Ltd. Anti-cd47/anti-lag-3 bispecific antibody, preparation method therefor and use thereof
WO2022072697A2 (en) * 2020-09-30 2022-04-07 Immetas Therapeutics, Inc. Bispecific binding molecules 2
GB202104104D0 (en) * 2021-03-24 2021-05-05 Liliumx Ltd Platform and method
CA3221866A1 (en) * 2021-06-09 2022-12-15 Shiyong GONG Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
WO2023006975A2 (en) * 2021-07-30 2023-02-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric proteins and methods of immunotherapy
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
WO2023114965A2 (en) * 2021-12-17 2023-06-22 Modex Therapeutics, Inc. Antigen binding polypeptide complexes containing extracellular domains of tnfsf ligands
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
CN116789834B (zh) * 2023-08-29 2023-10-27 苏州为度生物技术有限公司天津分公司 一种抗人cd56工程抗体及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3103875A1 (en) * 2008-07-21 2016-12-14 Apogenix AG Tnfsf single chain molecules
WO2011109789A2 (en) * 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
RU2019126655A (ru) * 2012-08-20 2019-11-12 Фред Хатчинсон Кансэр Рисёч Сентер Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль
CN104718223A (zh) * 2012-08-20 2015-06-17 格利克尼克股份有限公司 具有抗原结合和多价FCγ受体结合活性的分子
DK2970486T3 (en) * 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
US11208480B2 (en) * 2014-06-27 2021-12-28 Innate Pharma Multispecific antigen binding proteins
MX2018012468A (es) * 2016-04-15 2019-06-06 Zymeworks Inc Construcciones de union a antigeno multiespecificas dirigidas a agentes inmunoterapeuticos.
WO2018144514A2 (en) * 2017-02-01 2018-08-09 Merrimack Pharmaceuticals, Inc. Tnf superfamily fusion polypeptides
WO2018213747A1 (en) * 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. 4-1bb agonist and cd40 agonist bispecific molecules

Also Published As

Publication number Publication date
CA3081353A1 (en) 2019-05-16
CN111315405A (zh) 2020-06-19
WO2019094574A1 (en) 2019-05-16
KR20200079536A (ko) 2020-07-03
TW201934583A (zh) 2019-09-01
BR112020008978A2 (pt) 2020-11-10
JP2021502360A (ja) 2021-01-28
EP3706786A1 (en) 2020-09-16
RU2020118832A (ru) 2021-12-09
US20190241659A1 (en) 2019-08-08
AU2018364562A1 (en) 2020-06-18
MX2020004801A (es) 2020-08-13
EP3706786A4 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
AR113692A1 (es) Polipéptidos de fusión biespecíficos y sus métodos de uso
PE20181005A1 (es) Anticuerpos biespecificos contra el a- beta humano y el receptor de transferrina humano y metodos de uso
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
PE20190562A1 (es) Proteinas de union biespecificas que se unen a una proteina inmunomoduladora y un antigeno tumoral
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
CL2018002687A1 (es) Proteínas de unión y métodos de uso de las mismas
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
NI201700001A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
CL2016001868A1 (es) Proteinas de union y sus métodos de uso
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
UY36687A (es) Anticuerpos contra ox40 y sus usos
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
CL2018003141A1 (es) Polipéptidos de fusión cd40l-fc y sus métodos de uso.
PE20231655A1 (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
DOP2017000052A (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos
PE20151772A1 (es) Proteinas especificas para el baff y para la b7rp1 y sus usos